Recurrent Soft Tissue Sarcoma Recruiting Phase 2 Trials for Ulixertinib (DB13930)

DBCOND0105100 (Recurrent Soft Tissue Sarcoma)Recruiting2 IdentifierTitlePurposeDrugs
NCT03155620Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)Screening
NCT03698994Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)Treatment